Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abpro HoldingsABPO -2.02%9 3-Year EBITDA Growth Rate is 77.90% as of Mar. 2026, which is at its 10-year median of 77.90. GuruFocus rates ABPO with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 1,131 Biotechnology companies, Abpro Holdings ranks better than 95.93% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 77.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Abpro Holdings was 77.90% per year. The lowest was 77.90% per year. And the median was 77.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Abpro Holdings 3-Year EBITDA Growth Rate Related Terms
ABPO vs SCNI, RMTG, CLSDQ: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Abpro Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abpro Holdings 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abpro Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Abpro Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 77.90% mean?
Abpro Holdings (ABPO) has a 3-Year EBITDA Growth Rate of 77.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Abpro Holdings and its competitors. This is near median its historical median of 77.90. Over the past decade, Abpro Holdings' 3-Year EBITDA Growth Rate has ranged from 77.90 to 77.90. According to the industry distribution chart, Abpro Holdings ranks #46 out of 1131 companies in the Biotechnology industry, placing it in the top 4.1%.
Is Abpro Holdings' 3-Year EBITDA Growth Rate too high?
Abpro Holdings' current 3-Year EBITDA Growth Rate of 77.90% is near median its 10-year median of 77.90. Over the past 10 years, this metric has ranged from a low of 77.90 to a high of 77.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Abpro Holdings' value of 77.90% is 422.8% above this industry median. Based on the distribution chart, Abpro Holdings ranks #46 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abpro Holdings has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Abpro Holdings' 3-Year EBITDA Growth Rate compare to SCNI and RMTG?
According to the Biotechnology industry distribution chart, Abpro Holdings ranks #46 out of 1131 companies for 3-Year EBITDA Growth Rate. This places Abpro Holdings in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.90. Abpro Holdings' value of 77.90% is 422.8% above this benchmark. Historically, Abpro Holdings' own 3-Year EBITDA Growth Rate has ranged from 77.90 to 77.90 over the past decade. While the company's 10-year median is 77.90 vs. the industry median of 14.90, Abpro Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abpro Holdings's current 3-Year EBITDA Growth Rate of 77.90% is 422.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Abpro Holdings and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abpro Holdings's current 3-Year EBITDA Growth Rate is 77.90%, which is near median its own 10-year median of 77.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abpro Holdings stock overvalued right now?
Abpro Holdings (ABPO) has a current 3-Year EBITDA Growth Rate of 77.90%. The current 3-Year EBITDA Growth Rate is 77.90%, which is near median its 10-year median of 77.90 and 422.8% above the Biotechnology industry median of 14.90. Abpro Holdings' overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Abpro Holdings (ABPO), the current 3-Year EBITDA Growth Rate is 77.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. The company is focused on novel antibody constructs for immuno-oncology, ophthalmology, and infectious diseases. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, the company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
9GF Score
Get the complete analysis for ABPO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABPO has been successfully added to your 
